Vaxxas Announces Initiation of Phase I Clinical Study of First Needle-Free COVID-19 Vaccine Delivered Using High-Density Microarray Patch (HD-MAP)
November 9, 2022
Vaxxas, a clinical-stage biotechnology company commercialising a novel vaccination platform, today announced the initiation of a Phase I clinical trial with the first needle-free COVID-19 vaccine candidate delivered using Vaxxas’ proprietary high-density microarray patch (HD-MAP) technology.
The Phase I Clinical Study is being conducted in Australia at the University of the Sunshine Coast’s Sippy Downs clinical research location.
This is a milestone step for Vaxxas towards seeking TGA and FDA approvals for a COVID-19 vaccine patch. Upon successful completion of the Phase I clinical study, and subsequent Phase II and Phase III studies, again if successful, the COVID-19 vaccine patch could be available as early as 2025.
The COVID-19 vaccine patch is based upon HD-MAP delivery of a SARS-CoV-2 spike subunit vaccine candidate from The University of Texas at Austin (UTA). The vaccine candidate is a second-generation version of the spike protein used in the major US-approved COVID-19 vaccines, and has been modified for stability and immunogenic response, giving potential coverage of all known SARS-CoV-2 variants. Results from preclinical animal studies completed in July of this year support the potential efficacy of the COVID-19 vaccine patch against all current variants of concern.
“Attaining this clinical milestone and building upon compelling preclinical data, we are excited by the rapid progress of our needle-free COVID-19 vaccine candidate,” said Vaxxas Chief Executive Officer David L. Hoey.
“Vaxxas’ HD-MAP technology can potentially enable cost-effective distribution without the need for extensive refrigeration, and our vaccination patch offers the potential for self-administration. This may enable an accelerated response in a pandemic situation and broader population coverage.”
The Phase I clinical trial will assess the safety, tolerability, and immunogenicity of the COVID-19 vaccine candidate in 44 healthy adults, aged 18 – 50 years inclusive, who have had three doses of an authorised COVID-19 vaccine, with the last dose received at least four months prior to participating in the study.
In addition to demonstrating the safety of the vaccine candidate, the trial is designed to gather signals related to antibody and T-cell responses to dosing with the patch-delivered vaccine candidate.
The highly stabilised protein within UTA’s COVID-19 vaccine candidate is designed to mimic the structure of the spike protein on the surface of the coronavirus to train the human immune system to recognise and fight SARS-CoV-2 infection.
“At a time when the world is facing more emerging variants of the COVID-19 virus, it’s especially important to continue to build out our arsenal of tools to prevent infection and serious disease,” said Jason McLellan, a professor of molecular biosciences and Welch Chair in Chemistry at The University of Texas at Austin.
“Clinical testing of this patch-based vaccine that uses UTA’s vaccine candidate represents a significant step towards equipping the globe for new phases of the fight against COVID-19.”
Preclinical research published in Science Advances and Vaccine and undertaken by The University of Queensland and collaborators demonstrated that the UTA vaccine candidate delivered using Vaxxas’ HD-MAP resulted in enhanced virus-neutralising antibody and T-cell responses against all known variants of concern, including alpha, beta, gamma, delta, and omicron, when compared to needle and syringe vaccination with the same vaccine.
“We are pleased to see our COVID-19 patch transition from the lab to Vaxxas for Phase I clinical trials,” Dr David Muller from The University of Queensland said.
“Our work demonstrated that the COVID-19 vaccine patch, when tested in mice, produces potent immune responses against every SARS-CoV-2 variant we tested, including delta and omicron in preclinical models. If these results translate to humans, this patch could be a great tool in the fight against COVID-19,” Dr Muller said.
“It is important to note that this is our first-in-human trial of the COVID-19 vaccine patch. We are starting at a very low dose with no adjuvants which we know are used regularly with vaccines to stimulate a greater immune response,” Mr Hoey said.
“As such, the primary endpoint is safety. If the vaccine proves safe, we have a lot of flexibility to increase the dose or supplement the vaccine with an industry-standard adjuvant or even mRNA delivery on the patch in future trials if we need or wish to drive an even greater immune response than what we see in the Phase I trial.”
– ENDS –
About the COVID-19 vaccine candidate
The University of Texas at Austin’s Professor Jason McLellan and his collaborators at the NIH are the designers of an early version of the SARS-CoV-2 spike protein that was genetically altered by swapping in two amino acids called prolines, used to stabilise the spike protein and allow the immune system to better fight off infection. The earlier spike protein is used in leading existing COVID-19 vaccines distributed in the United States and others approved under emergency use authorisation in multiple countries.
In 2020, McLellan and his lab teamed up with the labs of two other UT Austin faculty members—Ilya Finkelstein, an associate professor in the Department of Molecular Biosciences, and Jennifer Maynard, a professor in the Cockrell School of Engineering—in designing a new spike protein, this time stabilised with six genetic alterations. In July of 2020, the team published findings in Science that the vaccine candidate induces immunologic expression of up to 10 times as much protein as the spike protein found in the current COVID-19 vaccines, making it a more powerful vaccine antigen for use in second generation COVID-19 vaccines.
About Vaxxas’ HD-MAP Technology and COVID-19 vaccine candidate
The Company’s proprietary HD-MAP technology platform utilises an ultra-high-density array of projections – invisible to the naked human eye – applied to the skin as a patch sitting inside a small applicator device. When applied to the skin, the patch delivers vaccine to the abundant immune cells immediately below the skin surface. This approach has the potential to enhance the efficiency and effectiveness of resulting immune responses of vaccines.
Vaxxas uses proprietary dry-coating technology to apply an active and stable vaccine onto the projections which offers the potential to eliminate the need for vaccine refrigeration during storage and transportation – reducing the resource and logistics burden of maintaining the refrigerated “cold chain”. Ease of use of the HD-MAP could enable simplified administration, potentially encompassing self-administration.To create the COVID-19 vaccine candidate, Vaxxas’ HD-MAP is coated with the vaccine and integrated into a single-use applicator, ready-for-vaccination. All vaccine candidates applied to the Vaxxas HD-MAP are designed to be effective and easy-to-use, while meeting industrial-scale manufacturing and commercial logistics requirements.
In extensive laboratory testing published in PLoS Med, Vaxxas’ HD-MAP delivered vaccines have been shown to be stable and remain active when stored and transported at room temperature and demonstrate potential for a lower dose when compared to needle and syringe delivery of vaccine antigens. Vaxxas has completed three human clinical studies with its HD-MAP involving more than 300 participants, demonstrating enhanced immune response of vaccine administration by HD-MAP.
About Vaxxas
Vaxxas is a privately held biotechnology company focused on enhancing the performance of existing and next-generation vaccines with its proprietary high-density microarray patch (HD-MAP). Vaxxas is targeting initial applications in infectious disease and oncology.
In addition to this Phase I clinical study of the COVID-19 vaccine candidate patch, Vaxxas is performing demonstration work in preparation for clinical evaluation under contract with the United States Biomedical Advanced Research and Development Authority (BARDA) on pandemic vaccination solutions.
Vaxxas’ core technology was initially developed at The University of Queensland (UQ), and the company was established as a start-up in 2011 by UQ’s commercialisation company UniQuest. The company was founded with the completion of an initial equity financing led by OneVentures Innovation Fund I with co-investors Brandon Capital Partners, Brandon BioCatalyst, and US-based HealthCare Ventures, followed by a further financing led by OneVentures. OneVentures Innovation Fund I and Brandon BioCatalyst are supported by the Australian Government’s Innovation Investment Fund (IIF) program. The IIF is an Australian Government venture capital initiative that provides investment capital and managerial expertise through licensed venture capital fund managers to investee companies. Learn more at www.one-ventures.com and www.brandoncapital.vc.
Disclaimer
Vaxxas’ HD-MAP delivered vaccines are under investigation and available only for investigational uses. They are not available anywhere in the world for sale or purchase. As such, Vaxxas makes no claim that the vaccines are reliable, durable, dependable, safe or effective, and makes no claim that it is superior to any other vaccine or vaccine delivery technology.
For media enquiries, please contact:
Amy Miller
WE Communication
+61 431 072 422
amymi@we-worldwide.com
